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Abstract 
The combination of Type 2 Diabetes Mellitus (T2DM) and Non-Alcoholic Fatty Liver Disease (NAFLD) has been a crucial problem. NAFLD 
means wide from Hepatic Steatosis (HS) to Nonalcoholic Steatohepatitis (NASH). NAFLD may be the predictor of causing Cardiovascular 
Disease (CVD). A dynamic association is found between NAFLD and Hepatic Insulin Resistance (IR). Treatments for T2DM and NAFLD 
include Glucagon-Like Peptide 1 Receptor Agonist (GLP-1 RA), Dipeptidyl-Peptidase 4 Inhibitors (DPP-4i) and Sodium-Glucose Cotransporter 
2 inhibitors (SGLT2i). An advanced NASH-specific agent is the Farnesoid X Receptor (FXR) agonist Obeticholic Acid (OCA). Further 
development of research and pharmaceutical industry will be expected. 
Keywords: Type 2 diabetes mellitus, Non-alcoholic fatty liver disease, Dipeptidyl-peptidase 4 inhibitors, Agonist obeticholic acid.
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FXR -Farnesoid X Receptor, OCA-Agonist Obeticholic Acid. 
 
 
Type 2 diabetes mellitus (T2DM) has become a major health problem 
worldwide [1]. Furthermore, the increase in obesity has brought a 
crucial issue of fatty liver or Non-Alcoholic Fatty Liver Disease 
(NAFLD). NAFLD has been the most common chronic liver disease in 
the world [2]. In fact, T2DM has high incidence of the complication of 
NAFLD, and NAFLD increases the risk of type 2 diabetes. 
Furthermore, T2DM may increase the risk for the progression from 
fatty liver to Nonalcoholic Steatohepatitis (NASH). NASH may will 
increase the risk of Liver Cirrhosis (LC) and Hepatocellular Carcinoma 
(HCC). In recent years, with the development of research, it has been 
reported that NASH fibrosis has improved [3]. In addition, various 
agents are used for diabetes may cause liver dysfunction. This article 
introduces clinical topics about T2DM and liver disease. 
 
The medical word NAFLD is an umbrella term. Then, it means 
multiple progressive liver disorders, from simple Hepatic Steatosis 
(HS) to NASH [4]. Approximately 35% of the cases with NASH shows 
progress to liver fibrosis and possibly to develop to HCC [5]. In 
European countries, NAFLD has been more prevalent with about 20-30 
% of total population and been possibly influencing 45-75% of patients 
with T2DM [6]. In recent decade, the prevalence of NAFLD has been 
increasing, which are along with the progressing situation of T2DM 
and obesity [7]. As a matter of fact, both of T2DM and NAFLD have 
common risk factors epidemiologically [8]. T2DM has been a major 
chronic common disease for long, while NAFLD has been relatively 
rather new. Consequently, various treatments for both diseases will be 
necessary to evaluate from combined points of view [9].  
 
 
NAFLD has been recently the most prevalent hepatic disease in the 
world and the most common etiology of hepatic disease for awaiting 
liver transplantation in adults of United States [10,11]. The presence of 
both T2DM and NAFLD will significantly show more incidence for 
developing NASH and LC, compared with the situation of NAFLD 
without continuing elevated glucose variability [8]. Some controversies 
are found that NAFLD may be the predictor of causing Cardiovascular 
Disease (CVD) with several discussions [12]. It is impressive situation 
that high mortality of NAFLD would be not from LC or HCC, but from 
exacerbated risk profiles of CVD associated with comorbidity of 
T2DM and other CVD risk factors [13]. Consequently, patients with 
both T2DM and NAFLD may have elevated CVD risk associated with 
increased mortality rates. As to NAFLD, there are recent advances of 
diagnosis and treatment of several phase III trials for NASH- specific 
therapies.  
 
There has been a dynamic association between NAFLD and Hepatic 
Insulin Resistance (IR). Therefore, several attempts were found 
administrating ant diabetic agents to treat NAFLD [14]. Systematic 
review was conducted for glucagon-like peptide 1 receptor agonist 
(GLP-1 RA), Dipeptidyl-Peptidase 4 inhibitors (DPP-4i), and sodium-
glucose cotransporter 2 inhibitors (SGLT2i) to treat T2DM, NAFLD 
relating with the improvement in Hepatosteatosis (HS) or 
Steatohepatitis (SH) [14]. These trials may support a future 
management paradigm for NAFLD in diabetics. However, further 
consideration will be needed. The relationship between commonly used 
for diabetes and hepatic function would be described as follows.  
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Regarding metformin, early studies showed improvement of surrogate 
outcomes, while no significant was found in the assessment of 
histological improvement [15]. In retrospective study of 191 cases of 
T2DM with biopsy-proven NASH and bridging fibrosis, metformin 
showed lower risk of overall mortality and liver transplant (HR:0.42) 
and HCC (sHR:0.25), respectively [16]. For current recommendations, 
pioglitazone or vitamin E are utilized as treatment options with biopsy-
proven NASH [15]. However, vitamin E can be recommended for only 
non-DM cases, and thiazolidinedione’s show the risk of congestive 
heart failure, weight gain, possibly bladder cancer and bone loss 
[15,17,18]. Among them, pioglitazone is the only diabetic medication 
in recent guidance from the American Association for the Study of 
Liver Diseases (AASLD) to treat cases with biopsy-proven NASH with 
or without T2DM [19].  
 
GLP-1 RAs especially increase insulin secretion, decrease glucagon 
secretion, slow gastric emptying, and decrease appetite [20]. GLP-1A 
was investigated for patients with NASH (the LEAN study), which was 
multicenter, double-blind, randomized, placebo-controlled phase two 
study [21]. Liraglutide group showed significant effect of NASH 
resolution compared with control group (p=0.019). Furthermore, 
semaglutide has been investigated in combination with other agents 
inhibiting hepatic de novo lipogenesis (DNL) and affecting acid-
enterohepatic access. GLP-1A has been reported to show the risk of 
acute pancreatitis, but the conflicting evidence is recently found [22]. 
 
SGLT2i inhibits glucose reabsorption in the proximal tubule of the 
kidney, which brings significant decrease of glucose and calorie. 
Consequently, SGLT2i shows effective function of weight reduction, 
improved insulin sensitivity and the reduction in liver fat content [23]. 
Serum aminotransferases were reduced by the administration of several 
kinds of SGLT2i agents. There was a recent study for empagliflozin for 
two groups of patients with T2DM and NAFLD [24]. It is an E-LIFT 
Trial, which stands for Effect of Empagliflozin on Liver Fat in Patients 
with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A 
Randomized Controlled Trial. Liver fat was measured by the magnetic 
resonance imaging proton density fat fraction (MRI-PDFF). In 
comparison with control group, empagliflozin group showed 
significantly decreased liver fat by the measurement of MRI-PDFF. 
The data was from 16.2% to 11.3%, p<0.0001 in Empagliflozin group, 
and 16.4% to 15.5%, not significant, p= 0.057. Further studies on 
RCTs are necessary to determine the efficacy of SGLT2i on liver 
histology in NASH.  
 
 For NASH management in the future, combination therapy would be 
recommended in patients with coexisting T2DM and NASH. One 
attracting combined agents in order to improve NASH and to reduce 
CVD risk may be included as follows: i) low dose pioglitazone and 
GLP-1A, ii) low dose pioglitazone and SGLT-2i. As regards to such 
combined therapy, future detail investigations would be needed to 
explore clinical effect in diabetic medical practice [19].  
  
In pharmaceutical industry worldwide, a new NASH-specific agent has 
been harnessing attention from federal and private funders. There were 
many trials on governmental registration. Among them, the farnesoid X 
receptor (FXR) agonist obeticholic acid (OCA) is an advanced agent 
[25]. FXR has been a nuclear receptor, which shows high expression in 
small intestine and liver. They regulate lipid/glucose homeostasis, 
increase insulin sensitivity, and modify the situation of liver fibrosis.  
 
In summary, recent topics concerning T2DM and NAFLD were 
described. Effective measures for many patients suffering these will be 
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